Suzhou Genhouse Bio Co., Ltd.

11 clinical trials · Sponsor

Record	Firm	Date
Phase 2 Clinical Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GH21 Capsules Combined With D-1553 Tablets in Subjects With Locally Advanced or Metastatic Solid Tumors With the KRASG12C Mutation (NCT07318649)	Suzhou Genhouse Bio Co., Ltd.	2025-12-30
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GH2616 in Subjects With Advanced Solid Tumor. (NCT07260513)	Suzhou Genhouse Bio Co., Ltd.	2025-03-27
A Phase Ia/Ib Clinical Study of GH56 Capsules in Subjects With MTAP-Deleted Advanced Solid Tumors (NCT06796699)	Suzhou Genhouse Bio Co., Ltd.	2025-03-07
GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors (NCT06435455)	Suzhou Genhouse Bio Co., Ltd.	2024-07-01
A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors (NCT06322095)	Suzhou Genhouse Bio Co., Ltd.	2024-03-22
A Phase Ia/Ib Study of GH2616 Tablet in Subjects With Advanced Solid Tumors (NCT06329206)	Suzhou Genhouse Bio Co., Ltd.	2024-03-20
A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC (NCT06306456)	Suzhou Genhouse Bio Co., Ltd.	2024-03-05
GH55 for Advanced Cancers With MAPK Mutations: A Study on Safety and Early Results (NCT06310382)	Suzhou Genhouse Bio Co., Ltd.	2022-12-07
GH35 Tablets for Advanced Solid Tumors: A Study on Safety and Early Results (NCT05010694)	Suzhou Genhouse Bio Co., Ltd.	2021-09-27

Every clearance here is in the API, with alerts when new ones post.